Nuvalent Inc (NUVL)
70.35
-2.14
(-2.95%)
USD |
NASDAQ |
May 03, 16:00
70.34
-0.01
(-0.01%)
Pre-Market: 20:00
Nuvalent Enterprise Value: 3.787B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 3.787B |
| May 02, 2024 | 3.924B |
| May 01, 2024 | 3.806B |
| April 30, 2024 | 3.693B |
| April 29, 2024 | 3.633B |
| April 26, 2024 | 3.564B |
| April 25, 2024 | 3.513B |
| April 24, 2024 | 3.585B |
| April 23, 2024 | 3.611B |
| April 22, 2024 | 3.412B |
| April 19, 2024 | 3.301B |
| April 18, 2024 | 3.320B |
| April 17, 2024 | 3.396B |
| April 16, 2024 | 3.428B |
| April 15, 2024 | 3.462B |
| April 12, 2024 | 3.477B |
| April 11, 2024 | 3.637B |
| April 10, 2024 | 3.568B |
| April 09, 2024 | 3.765B |
| April 08, 2024 | 3.665B |
| April 05, 2024 | 3.778B |
| April 04, 2024 | 3.887B |
| April 03, 2024 | 4.021B |
| April 02, 2024 | 3.984B |
| April 01, 2024 | 4.219B |
| Date | Value |
|---|---|
| March 28, 2024 | 4.091B |
| March 27, 2024 | 4.190B |
| March 26, 2024 | 4.133B |
| March 25, 2024 | 4.177B |
| March 22, 2024 | 4.254B |
| March 21, 2024 | 4.376B |
| March 20, 2024 | 4.387B |
| March 19, 2024 | 4.282B |
| March 18, 2024 | 4.284B |
| March 15, 2024 | 4.457B |
| March 14, 2024 | 4.700B |
| March 13, 2024 | 4.944B |
| March 12, 2024 | 4.855B |
| March 11, 2024 | 4.639B |
| March 08, 2024 | 4.687B |
| March 07, 2024 | 4.627B |
| March 06, 2024 | 4.692B |
| March 05, 2024 | 4.496B |
| March 04, 2024 | 4.726B |
| March 01, 2024 | 4.865B |
| February 29, 2024 | 4.669B |
| February 28, 2024 | 4.749B |
| February 27, 2024 | 4.981B |
| February 26, 2024 | 4.829B |
| February 23, 2024 | 4.871B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
84.79M
Minimum
May 16 2022
4.981B
Maximum
Feb 27 2024
1.647B
Average
1.258B
Median
Enterprise Value Benchmarks
| Geron Corp | 1.971B |
| Verastem Inc | 178.81M |
| Karyopharm Therapeutics Inc | 109.50M |
| Syndax Pharmaceuticals Inc | 1.296B |
| AnaptysBio Inc | 320.46M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -38.29M |
| Total Expenses (Quarterly) | 46.44M |
| EPS Diluted (Quarterly) | -0.62 |
| Earnings Yield | -3.07% |